Keeping Track: J&J’s Targeted Oncologic Rybrevant, Apellis’ C3 Inhibitor Empaveli Approved; New Filings From Takeda, Lilly

Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers